6月27日，爱康集团联合新京报发布了《2025版北京市体检人群抽样健康报告》（以下简称《北京健康 报告》）。报告由北京大学中国卫生经济研究中心提供学术支持，以2024年4月1日至2025年3月31日期 间在爱康集团旗下北京体检中心参加体检的人群为研究对象，旨在通过体检大数据呼吁民众关注自身健 康，提升对于一年一次的健康体检的重视程度。 自2021年针对旗下体检中心参加体检的城市人群健康问题开展跟踪研究，并发布《城市人群健康报告》 系列以来，这是爱康第四次针对北京市体检人群发布健康报告。本次报告共收集148.3万人次数据，选 择了22项体检异常结果进行统计，统计维度包括心血管类体检异常结果、代谢和内分泌类体检异常结 果、消化系统类体检异常结果和性别相关的体检异常结果等。 《北京健康报告》显示，从30岁开始，各个年龄段北京市男性体检人群体重指数增高检出率均超过 67%，且男性体检人群在各个年龄段的体重指数增高检出率均高于女性；甲状腺癌成为目前随访到的人 群中患病人数最多的癌种。 扫码查看完整《北京健康报告》 骨量减少/骨质疏松（骨密度）、BMI增高异常指标检出率过半 从《北京健康报告》统计（排除与性别相关的前列腺 ...

"年年参加体检，为什么还是突然查出癌症晚期？"一些人每年做一次体检，却没有及时查出恶性肿瘤， 错过最佳治疗时间。其实，常规体检不等于癌症筛查，一些癌症只有通过专项筛查才能发现。 培养健康生活方式。意识来源于实践，个人健康意识也在日常生活方式中得到培养和巩固。医学研究表 明，在影响健康的各类因素中，生活方式和行为因素占到60%。因此，改变不健康行为，践行健康的生 活方式对健康具有重要意义。培养健康生活方式，个人要努力做到合理膳食、适量运动、戒烟限酒、心 理平衡，同时也要养成文明卫生的生活习惯，避免传染病的发生；公共层面应增加运动锻炼设施，加强 健康生活方式引导，努力为居民营造健康生活氛围。 做好个人健康管理。健康管理包括健康监测、健康干预、健康预防等，积极参与健康管理可以促进个人 对健康的全面认识。定期做好科学体检是健康监测的关键。在不同的年龄阶段要进行不同的体检项目， 年长阶段应该着重恶性肿瘤等重大疾病筛查。研究显示，超重肥胖是许多慢性病的诱因。积极参与体重 管理，经常参加运动锻炼，注意控制饮食，有利于保持良好体型，预防慢性病。去年，国家卫生健康委 启动了为期3年的"体重管理年"活动，各地、各部门、各单位也积 ...

Financial Data and Key Metrics Changes - In the first quarter, the company delivered 1,200,000 total results to patients, with core revenue growing by 11% and non-GAAP operating expenses increasing by only 4%, leading to a more than 60% increase in adjusted EBITDA [6][11][12] - Screening revenue exceeded guidance, increasing by 14% to $540 million, while Precision Oncology revenue grew by 4% to $167 million on a core basis [11][12] - Adjusted EBITDA increased by 61% to $63 million, with adjusted EBITDA margin expanding by 280 basis points [12][18] Business Line Data and Key Metrics Changes - Cologuard growth was driven by rescreens, CareGAP programs, and new ordering providers, with rescreens now accounting for over 25% of total Cologuard orders [11][55] - The CareGAP program grew triple digits last year and is expected to continue strong double-digit growth this year [9][12] - The launch of Cologuard Plus is anticipated to deliver increased value, improved performance, and higher adoption rates [10][19] Market Data and Key Metrics Changes - Customer engagement by the field force increased by over 30% year over year, with more than 190,000 providers ordering during the first quarter, marking a nearly 10% increase year over year [16][32] - The company ended the quarter with cash and securities of $786 million, reflecting a $249 million convertible note paydown [14] Company Strategy and Development Direction - The company is focused on enhancing its commercial execution, with a purpose-built commercial organization and expanded field team engaging providers at record rates [6][8] - The launch of Cologuard Plus is positioned to revolutionize colorectal cancer screening, with a focus on making it the first option in healthcare provider screening toolkits [19][20] - The company is also advancing its precision oncology portfolio with the launch of OncoDetect, aimed at benefiting six million cancer patients [21][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong start in 2025, highlighting the successful launch of two innovative products and the positive impact of commercial improvements [25] - The company expects continued revenue growth, with total revenue guidance increased to between $3.07 billion and $3.12 billion for the year [14][15] - Management noted that they are on track to generate meaningful free cash flow growth through productivity and working capital initiatives [13][14] Other Important Information - The company has taken actions to optimize costs, expecting annual savings of $18 million, with $9 million coming in 2025 [13] - The launch of CancerGuard is planned for the second half of 2025, enabling population-level screening for cancer [24] Q&A Session Summary Question: Focus on commercial execution and changes made - Management highlighted that the volume of calls by sales representatives is up, with a 10% increase in per-rep productivity, indicating an engaged sales force [30][32] Question: Guidance unpacking and revenue outlook - Management indicated that the increased guidance is primarily due to improvements in commercial execution, with expectations of 13% growth in the first half and 15% in the second half of the year [40] Question: Sales and marketing investments - Management acknowledged higher sales and marketing expenses but emphasized that revenue growth significantly outpaced these investments, indicating effective leverage [45] Question: Rescreens contribution to total volume - Management confirmed that rescreens are a significant growth driver and could contribute a couple of points to overall volume this year [56] Question: Blood testing pipeline and timeline - Management expressed confidence in the timeline for blood testing developments, with a readout expected in midsummer [68][79] Question: Cologuard Plus traction and mix - Management reported that Cologuard Plus is currently available for Medicare Part B patients, with expectations for growth as more payers contract for coverage [82][85] Question: Commercial payer discussions and pricing for CancerGuard - Management indicated positive discussions with payers regarding Cologuard Plus and noted that pricing for CancerGuard has not yet been finalized [90]

根据弗若斯特沙利文的资料， 觅瑞 是开发及商业化用于癌症及其他疾病早期检测 的、精准的、无 创的、可负担的、基于血液的miRNA检测试剂盒的先驱者与领导者 ； 根据弗若斯特沙利文的资料， 觅瑞 是全球为数不多的已获得分子癌症筛查行业IVD产品监管批准的公司之一，同时也是全球范围 内首家且唯一一家获得分子胃癌筛查IVD产品监管批准的公司。 今年上半年，核心产品GASTROClear的毛利率超80%。 本文为IPO早知道原创 作者｜Stone Jin 微信公众号｜ipozaozhidao 据IPO早知道消息，Mirxes Holding Company Limited（以下简称"觅瑞"）于11月4日更新招股 书，继续推进港交所主板上市进程，中金公司和建银国际担任联席保荐人。 成立于2014年的觅瑞作为一家起源于新加坡的微小核糖核酸("miRNA")技术公司，专注于在全球范 围内普及疾病筛查诊断解决方案。 截至2024年10月31日，觅瑞拥有一种核心产品(即GASTROClear)、两种其他商业化产品(即 LungClear及Fortitude)以及六种处于临床前阶段的候选产品。 其中，觅瑞的核心产品GASTROC ...